Schering Corporation

Embera Neurotherapeutics, Inc.

Wing-Kee P. Cho

Winston a. Vadino

Imtiaz a. Chaundry

Stephen M. Liebowitz

Frank E. Bowen

Elliot I. Stupak

Imtiaz a. Chaudry

Winston A Vadino

Imtiaz A Chaudry

Surendra A Sangekar

Elliot I Stupak

Stephen M Liebowitz

Frank E Bowen

Ping I Lee

Gayda Hanna

Wing-Kee Philip Cho

Eugenio A Cefali

Julie A Straub

Bruce Rehlaender

Muralikrishna Duvvuri

Parag M Ved

Jay Breaux

Kripanath Borah

Carol Gloff

Imtiaz A Chaundry

Wing-Kee P Cho

Provided are pharmaceutical compositions useful for the treatment and/or prevention of a disorder, such as addiction. For example, pharmaceutical compositions are provided that comprise a first active pharmaceutical component (e.g., metyrapone) and a second active pharmaceutical component (e.g., oxazepam). The compositions may be constructed in such a manner as to limit the physical contact between the first and second active pharmaceutical components, thus preventing any degradation of the active pharmaceutical components resulting form interaction between the two components. The compositions may include at least one pharmaceutically acceptable excipient. Also provided are methods of making the compositions as well as kits containing materials to provide the compositions.

Pharmaceutical compositions and uses thereof

An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin and a process for making such solid dosage forms are disclosed.

Orally administrable solid ribavirin dosage forms and process for making them

An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin is disclosed.

Orally administrable solid dosage form

An orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is subsantially free of polymorphic forms of ribavirin is disclosed.

A pharmaceutical composition in the form of a substantially amorphous solid solution comprising an antifungal compound of the formula I: ##STR1## wherein: X is F; and R.sub.1 is ##STR2## or an ester or ether of said compound of Formula I; and a soluble or insoluble polymer such as: povidone or crospovidone, wherein the ratio of said compound to said polymer is about 1:3 to about 1:6 is disclosed.

Solid solution of an antifungal agent with enhanced bioavailability

A process of making an orally administrable solid dosage form containing a compacted ribavirin composition having an advantageously high tap density of at least 0.6 g/mL as well as surprisingly rapid disintegration and dissolution rates and wherein the ribavirin is substantially free of polymorphic forms of ribavirin as determined is disclosed.

Process of making solid ribavirin dosage forms

Oral antifungal composition

Antifungal composition with enhanced bioavailability

Pharmaceutical compositions for use in the treatment of cough/cold symptoms comprising loratadine, ibuprofen and pseudoephedrine are disclosed.

Sustained release tablet comprising loratadine, ibuprofen and

A long acting diltiazem formulation is disclosed that comprises more than 35 percent by weight of a swellable hydrophilic polymer. Release rate is also controlled by the application of diffusion controlled membrane to the matrix tablet containing swellable hydrophilic polymers. The diffusion rate through the membrane depends upon the composition or ratio of hydrophilic to hydrophobic coating agent.

Long acting diltiazem formulation

An immediate release diltiazem tablet is disclosed that exhibits an unexpectedly rapid bioavailability profile when the active ingredient is diltiazem.

Immediate release diltiazem formulation

Pharmaceutical composition comprising loratadine, ibuprofen and

A sustained release dosage form of labetalol hydrochloride is disclosed comprising the active ingredient in a polymeric matrix of hydroxypropylmethylcellulose and polyvinylpyrrolidone and a pharmaceutically acceptable organic acid.

Sustained release labetalol tablets

The invention relates to a controlled release dosage form comprising three actives: acetaminophen, pseudoephedrine and dexbrompheniramine.

Growing community of inventors

Whitehouse Station, NJ, United States of America

Winston A Vadino